Research programme: cancer therapeutics and diagnostics - OncoTAb

Drug Profile

Research programme: cancer therapeutics and diagnostics - OncoTAb

Alternative Names: Monoclonal antibody - OncoTAb; TAB 004

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator OncoTAb
  • Class Antibodies; Antibody diagnostics; Diagnostic agents; Radiopharmaceuticals
  • Mechanism of Action Diagnostic imaging enhancers; Mucin 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Pancreatic cancer

Highest Development Phases

  • Preclinical Breast cancer; Pancreatic cancer

Most Recent Events

  • 19 Oct 2016 Research programme: cancer therapeutics and diagnostics - OncoTAb is available for licensing as of 19 Oct 2016. https://www.oncotab.com/science-technology/
  • 19 Oct 2016 OncoTAB has patents pending for cancer therapeutics and diagnostics worldwide (OncoTAB website,
  • 05 Oct 2016 OncoTAb receives SBIR grant from the National Cancer Institute for radionuclide monoclonal antibody development in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top